17 results on '"N. Tourkantoni"'
Search Results
2. ISSUES AFFECTING THE NEUROPSYCHOLOGICAL INTERVENTION FORMULATION: A PEDIATRIC CASE STUDY
- Author
-
N Karra, O Dimos, E Saleptsi, K Varotsi, CS Karatosidi, N Tourkantoni, and C Kattami
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
We report a case-study of an 11.5 years-old male pediatric oncology patient, in order to discuss the necessity of considering multiple factors during the formulation of the intervention. He was diagnosed with an extensive and exceptionally malignant brain tumor (WHO Grade IV sarcoma) in the left occipitoparietal region with lung metastases, at the age of seven months. He underwent multiple surgeries, chemotherapy, irradiation therapy and v/p shunt placement. Follow-up imaging revealed tumor relapse in the right frontal region at the age of four, for which he underwent craniotomy and total resection. Finally, a surgery for v/p shunt replacement was performed after infection. He presented with multiple neurological deficits (gait disturbance and postural instability, right hemiparesis, motor and visuomotor coordination difficulties, fine and gross motor skills difficulties). He was referred for a neuropsychological evaluation and rehabilitation intervention. His performance revealed severe deficits in the domains of processing speed (>-2sd), visuospatial perception (>-2sd), verbal and visual memory (between -1sd and -3sd), and executive functions (>-2sd). Interestingly, attention abilities were intact (between -0.5 and +0.5 standard deviation from the normative mean). Clinical observations during the assessment did not reveal the typical behavioral, emotional and functional profile of brain injury (apathy, disinhibition, emotional fluctuations), though a wide range of compensatory strategies were observed. Finally, his environment reported good functionality in daily living. With the initiation of the intervention and introduction to novel and unpredictable situations, the abovementioned cognitive deficits, as well as emotional and behavioral disturbances raise questions regarding the formulation of the intervention.
- Published
- 2018
- Full Text
- View/download PDF
3. PB1836 BURKITT LEUKEMIA/LYMPHOMA IN CHILDREN: CYTOGENETIC CHARACTERISTICS AND OUTCOME
- Author
-
A. Zampogiannis, M. Moschovi, N. Tourkantoni, M. Kanariou, C. Kanaka, and M. Tzanoudaki
- Subjects
Oncology ,medicine.medical_specialty ,Leukemia lymphoma ,business.industry ,Internal medicine ,medicine ,Hematology ,business ,Outcome (game theory) - Published
- 2019
- Full Text
- View/download PDF
4. Immune Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Desferrioxamine Chelation Treatment
- Author
-
V Tzimouli, Miranda Athanassiou-Metaxa, N. Tourkantoni, Anna Taparkou, Marina Economou, and F. Kanakoudi-Tsakalidou
- Subjects
Adult ,Immune status ,Adolescent ,Pyridones ,business.industry ,beta-Thalassemia ,Beta thalassemia ,Hematology ,General Medicine ,Deferoxamine ,Pharmacology ,medicine.disease ,Immunophenotyping ,chemistry.chemical_compound ,chemistry ,medicine ,Humans ,Deferiprone ,Chelation ,Child ,business ,Chelating Agents ,medicine.drug - Published
- 2003
- Full Text
- View/download PDF
5. Contents Vol. 110, 2003
- Author
-
K. Méhes, Marcel P. Devetten, Rafael Cardenas, Costas Tsatalas, Emma Cacciola, G. Melegh, B. Melegh, M. Economou, Ioannis Kotsianidis, J. David Gómez-Rangel, Jame Abraham, Guillermo J. Ruiz-Argüelles, Tim Holland-Letz, Yasutaka Aoyama, Z. Szolnoki, Á. Nagy, Vasiliki Kaloutsi, Rossella R. Cacciola, Evangelia Yannaki, Emanuel Spanoudakis, Giuliana G. Guarnaccia, E. Papp, J. Stankovics, L. Romics, Shinsaku Imashuku, Solveig G. Ericson, Anil Vachani, Orhan Türken, Despina Pantelidou, H. ten Cate, Adriano M. Arantes, Hisako Shibata, Ikuyo Ueda, Miklos L Auber, K. Tóth, A. Taparkou, Chikahiko Sakamoto, M. Ghosh, Tsugiko Shimizu, Shigeyoshi Hibi, K. Komlósi, Luis Servin-Abad, Charles L. Beall, Pam Bunner, Karsten Eisenblätter, Maria Stella Figueiredo, Özkan Sayan, Enes Murat Atasoyu, Richard Aplenc, F. Kanakoudi-Tsakalidou, Michael Krieg, Carmen Ferlito, Wendy Glatfelter, Muzaffar H. Qazilbash, Liliana Rivadeneyra, Axel Stachon, Jong Weon Choi, N. Tourkantoni, Manfred Köller, Taro Hasegawa, Genju Koh, Photios Iordanidis, Robin Weisenborn, Masayuki Hino, Hirohisa Nakamae, Ioannis Manavis, Eric L. Sievers, Rosario Giustolisi, Dimitris Margaritis, Beatriz Pérez-Romano, Anastasios J. Karayiannakis, Javier Casillas, Sumi Kusunose, Panayotis Kaloyannidis, Alejandro Ruiz-Argüelles, G. Mózsik, Vassilios Penopoulos, Guillermo J. Ruiz-Delgado, M. Athanassiou-Metaxa, G. Kosztolányi, Ioanna Sakellari, Perla Vicari, Yoshiki Terada, Takahisa Yamane, P. Smits, Achilles Anagnostopoulos, Alexandros Polychronidis, Joseph P. Lynch, Ernesto Di Francesco, Humberto Caldera, B. Gasztonyi, Ahmet Ozturk, V. Tzimouli, A. Császár, David Gómez-Rangel, George Bourikas, J. Bene, Peggy Han, Zafiris Kartasis, Charalambos Kartsios, and V. Havasi
- Subjects
Hematology ,General Medicine - Published
- 2003
- Full Text
- View/download PDF
6. Subject Index Vol. 110, 2003
- Author
-
Anastasios J. Karayiannakis, Despina Pantelidou, Humberto Caldera, Rafael Cardenas, Evangelia Yannaki, Emanuel Spanoudakis, Tim Holland-Letz, George Bourikas, J. Bene, Solveig G. Ericson, K. Tóth, Peggy Han, Giuliana G. Guarnaccia, B. Melegh, Pam Bunner, Ioannis Kotsianidis, Wendy Glatfelter, J. David Gómez-Rangel, Sumi Kusunose, K. Komlósi, Á. Nagy, Anil Vachani, Luis Servin-Abad, K. Méhes, Marcel P. Devetten, A. Taparkou, Achilles Anagnostopoulos, Maria Stella Figueiredo, Photios Iordanidis, Vasiliki Kaloutsi, Chikahiko Sakamoto, E. Papp, Costas Tsatalas, Carmen Ferlito, Jame Abraham, Guillermo J. Ruiz-Argüelles, Dimitris Margaritis, Vassilios Penopoulos, Emma Cacciola, Rossella R. Cacciola, Miklos L Auber, M. Economou, Özkan Sayan, Axel Stachon, Guillermo J. Ruiz-Delgado, Ahmet Ozturk, F. Kanakoudi-Tsakalidou, Enes Murat Atasoyu, Liliana Rivadeneyra, Jong Weon Choi, Masayuki Hino, H. ten Cate, Muzaffar H. Qazilbash, Yoshiki Terada, G. Melegh, Adriano M. Arantes, Ioannis Manavis, Charles L. Beall, Yasutaka Aoyama, Rosario Giustolisi, J. Stankovics, Javier Casillas, Panayotis Kaloyannidis, Alejandro Ruiz-Argüelles, Zafiris Kartasis, Hisako Shibata, Taro Hasegawa, V. Tzimouli, Tsugiko Shimizu, Charalambos Kartsios, V. Havasi, David Gómez-Rangel, Alexandros Polychronidis, Shinsaku Imashuku, Ernesto Di Francesco, B. Gasztonyi, A. Császár, Richard Aplenc, Hirohisa Nakamae, Beatriz Pérez-Romano, Orhan Türken, Karsten Eisenblätter, Michael Krieg, Eric L. Sievers, Genju Koh, G. Mózsik, Ioanna Sakellari, Perla Vicari, M. Ghosh, Shigeyoshi Hibi, Takahisa Yamane, P. Smits, Joseph P. Lynch, M. Athanassiou-Metaxa, N. Tourkantoni, Robin Weisenborn, G. Kosztolányi, Ikuyo Ueda, Z. Szolnoki, L. Romics, and Manfred Köller
- Subjects
Index (economics) ,Statistics ,Subject (documents) ,Hematology ,General Medicine ,Mathematics - Published
- 2003
- Full Text
- View/download PDF
7. Expression of DNA Repair Genes in Ewing Sarcoma.
- Author
-
Kyriazoglou A, Moutafi M, Zografos E, Konteles V, Sofianidis G, Mahaira L, Papakosta A, Tourkantoni N, Patereli A, Stefanaki K, Tzotzola V, Mpaka M, Polychronopoulou S, Dimitriadis E, and Kattamis A
- Abstract
Background/aim: Ewing sarcoma is an aggressive mesenchymal malignancy commonly affecting children and young adolescents. The molecular basis of this neoplasia is well reported with the formation of the EWSR1/FLI1 fusion gene being the most common genetic finding. However, this fusion gene has not been targeted therapeutically nor is being used as a prognostic marker. Its relevance regarding the molecular steps leading to Ewing sarcoma genesis are yet to be defined. The generation of the oncogenic EWSR1/FLI1 fusion gene, can be attributed to the simultaneous introduction of two DNA double-strand breaks (DSBs). The scope of this study is to detect any association between DNA repair deficiency and the clinicopathological aspects of Ewing's sarcoma disease., Patients and Methods: We have conducted an expression analysis of 35 patients diagnosed with Ewing sarcoma concerning the genes involved in non-homologous end joining (NHEJ) and homologous recombination (HR) repair pathways. We have analyzed the expression levels of 6 genes involved in NHEJ (XRCC4, XRCC5, XRCC6, POLλ, POLμ) and 9 genes involved in HR (RAD51, RAD52, RAD54, BRCA1, BRCA2, FANCC, FANCD, DNTM1, BRIT1) using real time PCR. Age, sex, location of primary tumor, tumor size, KI67, mitotic count, invasion of adjacent tissues and treatment were the clinicopathological parameters included in the statistical analysis., Results: Our results show that both these DNA repair pathways are deregulated in Ewing sarcoma. In addition, low expression of the xrcc4 gene has been associated with better overall survival probability (p=0.032)., Conclusion: Our results, even though retrospective and in a small number of patients, highlight the importance of DSBs repair and propose a potential therapeutic target for this type of sarcoma., Competing Interests: All Authors have no conflicts of interest for the entire content of this manuscript., (Copyright 2024, International Institute of Anticancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
8. A Case Series of BCOR Sarcomas With a New Splice Variant of BCOR/CCNB3 Fusion Gene.
- Author
-
Kyriazoglou A, Tourkantoni N, Liontos M, Zagouri F, Mahaira L, Papakosta A, Michali D, Patereli A, Stefanaki K, Tzotzola V, Skoura E, Baka M, Polychronopoulou S, Kattamis A, and Dimitriadis E
- Subjects
- Biomarkers, Tumor genetics, Child, Cyclin B, Greece, Humans, In Situ Hybridization, Fluorescence, Repressor Proteins genetics, Retrospective Studies, Proto-Oncogene Proteins genetics, Sarcoma diagnosis, Sarcoma genetics
- Abstract
Background/aim: Undifferentiated round cell sarcomas are a heterogeneous group of sarcomas. Identification of BCOR alterations, such as BCOR/CCNB3 and BCOR/MAML3 fusion genes and BCOR ITD has recently contributed in the precise diagnosis of these neoplasms, defining a new entity of the current classification of soft tissue and bone sarcomas. BCOR sarcomas share both morphological and genetic characteristics distinct from Ewing sarcomas. The scope of our study was to retrospectively identify BCOR sarcomas and find the correlations with the clinical outcome of these patients., Patients and Methods: Histopathology and immunohistochemistry of pediatric tumor samples were combined with molecular testing (PCR) and fluorescent in situ hybridization to find BCOR sarcomas., Results: We, herein, present our experience with BCOR sarcomas in a referral center of Greece. Moreover, we report in one case the detection of a variant BCOR/CCNB3 fusion not previously described., Conclusion: We are the first to report a splice variant of BCOR/CCNB3 which reveals the central position of BCOR in the oncogenesis of these tumors, furthermore we highlight the importance of molecular diagnostics in Ewing-like sarcomas and discuss the current treatment options for this rare entity., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
9. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
- Author
-
Filippidou M, Avgerinou G, Tsipou H, Tourkantoni N, Katsibardi K, Vlachou A, Roka K, Solomou E, and Kattamis A
- Subjects
- Adolescent, Antilymphocyte Serum therapeutic use, Child, Child, Preschool, Cyclosporine therapeutic use, Female, Follow-Up Studies, Humans, Immunosuppressive Agents therapeutic use, Male, Off-Label Use, Treatment Outcome, Anemia, Aplastic drug therapy, Benzoates therapeutic use, Hydrazines therapeutic use, Pyrazoles therapeutic use, Receptors, Thrombopoietin agonists
- Published
- 2020
- Full Text
- View/download PDF
10. A prospective study on the epidemiology and clinical significance of viral respiratory infections among pediatric oncology patients.
- Author
-
Vliora C, Papadakis V, Doganis D, Tourkantoni N, Paisiou A, Kottaridi C, Kourlamba G, Zaoutis T, Kosmidis H, Kattamis A, Polychronopoulou S, Goussetis E, Giannouli G, Syridou G, Priftis K, and Papaevangelou V
- Subjects
- Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Prevalence, Prospective Studies, Hospitalization, Influenza, Human diagnosis, Influenza, Human drug therapy, Influenza, Human epidemiology, Neoplasms epidemiology, Neoplasms therapy, Oseltamivir administration & dosage
- Abstract
Respiratory infections in oncology are both common and potentially severe. However, there is still a gap in the literature, regarding the epidemiology of viral respiratory infections in children with cancer. We prospectively enrolled 224 patients, from September 2012 to August 2015. The cohort included children with hematologic or solid malignancies receiving chemotherapy, or undergoing hemopoietic stem cell transplantation, outpatients/inpatients exhibiting signs/symptoms of febrile/afebrile upper/lower respiratory infection. Viral infection was diagnosed by detection of ≥1 viruses from a sample at time of enrollment, using the CLART
® PneumoVir kit (GENOMICA, Spain). Α detailed questionnaire including demographics and medical history was also completed. Samples were processed in batches, results were communicated as soon as they became available. Children recruited in whom no virus was detected composed the no virus detected group. Viral prevalence was 38.4% in children presenting with respiratory illness. A single virus was found in 30.4%, with RSV being the most frequent. Viral coinfections were detected in 8%. Children with viral infection were more likely to be febrile upon enrollment and to present with lower respiratory signs/symptoms. They had longer duration of illness and they were more likely to receive antibiotics/antifungals. Only 22% of children with influenza received oseltamivir. Mortality was low (2.7%), however, pediatric intensive care unit (PICU) admission and death were correlated with virus detection. In our study mortality was low and PICU admission was related to virus identification. Further research is needed to clarify whether antibiotics in virus-proven infection are of value and underline the importance of oseltamivir's timely administration in influenza.- Published
- 2019
- Full Text
- View/download PDF
11. Successful long-term hematological and immunological reconstitution by autologous cord blood transplantation combined with post-transplant immunosuppression in two children with severe aplastic anemia.
- Author
-
Avgerinou G, Oikonomopoulou C, Kaisari A, Ioannidou E, Komitopoulou A, Paisou A, Tourkantoni N, Filippidou M, Kattamis A, Vessalas G, Peristeri I, Goussetis E, and Kitra V
- Subjects
- Anemia, Aplastic blood, Anemia, Aplastic immunology, Child, Preschool, Combined Modality Therapy, Humans, Infant, Male, Transplantation, Autologous, Anemia, Aplastic therapy, Cord Blood Stem Cell Transplantation methods, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use
- Abstract
aUCBT is a valuable curative option in pediatric patients with refractory idiopathic SAA and no available matched sibling or unrelated donors. Experience in the use of autologous cord blood units in patients with SAA is limited and private for-profit cord blood-banking programs are controversial. We report the successful treatment of two patients with SAA, aged 15 and 24 months, with autologous cord blood combined with immunosuppression. After conditioning with 200 mg/kg cyclophosphamide and ATG, 7.5 mg/kg, 32.2 × 10
7 /kg, and 3.8 × 107 /kg autologous cord blood nucleated cells were infused, respectively. One of our patients underwent transplantation after failure of IST. Both patients received post-transplant immunosuppression with cyclosporine for 12 months. They remain disease-free 6 years post-transplantation., (© 2018 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
12. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
- Author
-
Moschovi M, Adamaki M, Athanasiadou A, Divane A, Karytianou A, and Tourkantoni N
- Subjects
- Antineoplastic Agents therapeutic use, Blast Crisis pathology, Child, Disease Progression, Drug Resistance, Neoplasm, Female, Humans, Imatinib Mesylate therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Protein Kinase Inhibitors therapeutic use, Treatment Outcome, Blast Crisis genetics, Fusion Proteins, bcr-abl genetics, Gene Deletion, Genetic Variation, Ikaros Transcription Factor genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
- Published
- 2015
- Full Text
- View/download PDF
13. Cranial Ewing's sarcoma in children.
- Author
-
Moschovi M, Alexiou GA, Tourkantoni N, Balafouta ME, Antypas C, Tsiotra M, Sfakianos G, and Prodromou N
- Subjects
- Adolescent, Astrocytoma radiotherapy, Brain Neoplasms radiotherapy, Facial Nerve Diseases surgery, Facial Paralysis surgery, Humans, Immunohistochemistry, Magnetic Resonance Imaging, Male, Particle Accelerators, Petrous Bone pathology, Radiopharmaceuticals, Sarcoma, Ewing etiology, Sarcoma, Ewing surgery, Skull Neoplasms etiology, Skull Neoplasms surgery, Technetium Tc 99m Medronate, Tomography, X-Ray Computed, Neoplasms, Radiation-Induced pathology, Sarcoma, Ewing pathology, Skull Neoplasms pathology
- Abstract
Ewing's sarcoma is a highly malignant neoplasm of bones which accounts for the 10% of primary bone malignancies. Primary Ewing's sarcoma of skull vault is very rare and constitutes 1-6% of all Ewing's sarcomas. We present a case of a primary and a radiation-induced skull Ewing's sarcoma. The symptoms, neuroimaging findings and the treatment for these cases are reviewed. Both children were operated with favorable outcome.
- Published
- 2011
- Full Text
- View/download PDF
14. Prognostic significance of angiogenesis in relation to Ki-67, p-53, p-27, and bcl-2 expression in embryonal tumors.
- Author
-
Moschovi M, Koultouki E, Stefanaki K, Sfakianos G, Tourkantoni N, Prodromou N, and Alexiou GA
- Subjects
- Adolescent, Child, Child, Preschool, Disease-Free Survival, Female, Gene Expression genetics, Humans, Immunohistochemistry, Male, Medulloblastoma mortality, Multivariate Analysis, Neoplasms, Germ Cell and Embryonal mortality, Prognosis, Rhabdoid Tumor mortality, Biomarkers, Tumor biosynthesis, Cranial Fossa, Posterior pathology, Ki-67 Antigen biosynthesis, Medulloblastoma metabolism, Membrane Proteins biosynthesis, Neoplasms, Germ Cell and Embryonal metabolism, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Rhabdoid Tumor metabolism, Skull Base Neoplasms metabolism, Tumor Suppressor Protein p53 biosynthesis
- Abstract
Aim: We investigated the angiogenesis and density of newly formed blood vessels in embryonal tumors in relation to Ki-67, bcl-2, p-53 and p-27 expression., Methods: Forty-five children with embryonal tumors were enrolled in the study. Forty patients had a medulloblastoma (MB) and 5 patients had atypical teratoid/rhabdoid tumor (AT/RT)., Results: In MB, the 5-year PFS and OS was 62.5 and 70%, respectively. Patients with Ki-67 index >50%, bcl-2 index >30% and higher density of new vessels were associated with worse survival. In the multivariate analysis, Ki-67 index was identified as a factor with independent prognostic power. In AT/RTs, high density of new vessels (>25 HRF) was observed in 3 patients and Ki-67 index over 25% was found in 4 patients., Conclusion: Increased Ki-67, bcl-2 and density of new vessels are of prognostic value for the disease outcome in MB., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
15. Efficacy and safety of linezolid in immunocompromised children with cancer.
- Author
-
Moschovi M, Trimis G, Tsotra M, Chatzi F, Karamolegou K, Santou A, Tourkantoni N, and Chrousos G
- Subjects
- Acetamides adverse effects, Age Factors, Anti-Infective Agents administration & dosage, Anti-Infective Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bacteremia immunology, Bacteremia microbiology, Bacteremia mortality, Child, Child, Preschool, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Gram-Positive Bacterial Infections diagnosis, Gram-Positive Bacterial Infections immunology, Gram-Positive Bacterial Infections mortality, Greece, Hematologic Neoplasms diagnosis, Hematologic Neoplasms drug therapy, Hematologic Neoplasms mortality, Humans, Infant, Infusions, Intravenous, Linezolid, Male, Oxazolidinones adverse effects, Prospective Studies, Risk Assessment, Severity of Illness Index, Survival Analysis, Treatment Outcome, Acetamides administration & dosage, Bacteremia drug therapy, Gram-Positive Bacterial Infections drug therapy, Hematologic Neoplasms immunology, Immunocompromised Host drug effects, Oxazolidinones administration & dosage
- Abstract
Background: The aim of this study was to determine the safety, tolerance and efficacy of linezolid for the treatment of infections from Gram-positive bacteria in immunocompromised children with cancer., Methods: This was a prospective non-comparative unblinded study in the Hematology/Oncology Unit over a two-year period, administering linezolid as monotherapy in children with cancer., Results: Seventeen children received linezolid (30 mg/kgr: 3 i.v. per day). Mean duration of linezolid administration was 12.2 days (range, 6-38 days), while the median age of the evaluable patients was 2.2 years (range, 6 months-11.2 years). Primary diagnosis was acute lymphoblastic leukemia (nine patients), brain tumor (three patients), multi-organ Langerhans cell histiocytosis (two patients), rhabdomyosarcoma, Burkitt's lymphoma and ovarian tumor (one patient each). All patients were in the midst of chemotherapy cycles. Ten out of 17 children had positive blood cultures (methicillin-resistant Staphylococcus aureus, four patients; vancomycin-resistant Enterococcus, three patients; penicillin-resistant Streptococcus pneumoniae, three patients), while seven of the 17 had fever and vancomycin-resistant Enterococcus in stool cultures. All patients were considered clinically cured after the end of the linezolid regimen (100% efficacy). The main adverse events were thrombocytopenia grade 1-3 and anemia grade 2-3 (four and two patients, respectively). Chemotherapy-induced myelotoxicity (six patients) was not worsened during linezolid therapy. No bleeding episodes were presented. Self-limited diarrhea grade 1-2 was presented in four patients (mean duration 2 days). The total adverse event rate was 23.5%; however, there was no premature cessation of linezolid in any patient., Conclusions: Linezolid may be another effective and safe therapy to treat infections from resistant Gram-positive bacteria in immunocompromised children, even in young ages., (© 2010 The Authors. Pediatrics International © 2010 Japan Pediatric Society.)
- Published
- 2010
- Full Text
- View/download PDF
16. Propranolol treatment for a giant infantile brain cavernoma.
- Author
-
Moschovi M, Alexiou GA, Stefanaki K, Tourkantoni N, and Prodromou N
- Subjects
- Antigens, CD34 metabolism, Blood Vessels metabolism, Blood Vessels pathology, Brain drug effects, Brain metabolism, Brain pathology, Brain Neoplasms pathology, Brain Neoplasms surgery, Hemangioma, Cavernous, Central Nervous System pathology, Hemangioma, Cavernous, Central Nervous System surgery, Humans, Infant, Iron metabolism, Magnetic Resonance Imaging, Male, Time Factors, Treatment Outcome, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Hemangioma, Cavernous, Central Nervous System drug therapy, Propranolol therapeutic use
- Published
- 2010
- Full Text
- View/download PDF
17. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
- Author
-
Tourkantoni N, Athanassiou-Metaxa M, Zafiriou D, Tzimouli V, Economou M, Taparkou A, Perifanis V, and Kanakoudi-Tsakalidou F
- Subjects
- Adolescent, Adult, Autoantibodies blood, B-Lymphocytes immunology, Chelation Therapy, Child, Deferiprone, Deferoxamine administration & dosage, Deferoxamine therapeutic use, Drug Therapy, Combination, Ferritins blood, Humans, Immunologic Factors blood, Iron Chelating Agents therapeutic use, Iron Overload drug therapy, Pyridones administration & dosage, Pyridones therapeutic use, T-Lymphocytes immunology, beta-Thalassemia immunology, beta-Thalassemia physiopathology, Evoked Potentials, Immune System physiology, beta-Thalassemia drug therapy
- Abstract
Deferiprone (L1), has previously been reported to be associated with immunological abnormalities in iron loaded thalassemia patients. However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO). During chelation therapy with DFO, several complications have been reported, which were due to pharmacological activity and high dose toxicity with regard to both acoustic and visual effects, as well as peripheral nerve disorders that were measured by nerve conduction velocities. The immune and neural status of 44 beta-thalassemic patients, aged 10-30 years (mean 19.4 +/- 4.9), receiving L1 as a monotherapy (n = 21), or in combination with DFO (n = 23), has been followed for 2 years by monitoring the level of immunoglobulins (IgG, IgM, IgA), the level of T and B lymphocytes (CD4/CD8), the auto antibodies: anti nuclear (ANA), anti-double-stranded (anti-ds DNA), anti reticulin (anti-R1), anti-extra nuclear (anti-ENA), anti histone (anti-AHA), anti liver-kidney-muscle (anti-LKM), anti-smooth muscle (anti-SMA), anti-thyroid (anti-ATA), anti-mitochondrial (anti-AMA) antibodies and the C-reactive protein. The percentage of patients with disorders of the immune and nervous system concerned very few cases. None of our patients with pathological findings in their immunological or neurophysiological examinations presented any signs or symptoms of involvement of the immune or nervous system. Further advantages have been identified for the oral use of L1 and its combination with DFO, including synergistic efficacy and lower dosing with limited toxicity.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.